北京商报讯(记者丁宁)4月15日,映恩生物(09606.HK)登录港交所,上市首日收涨116.7%,收盘价为205港元/股,总市值为175.1亿港元。 招股书显示,映恩生物是一家专注于抗体偶联药物(ADC)研发的全球领跑企业,聚焦癌症及自身免疫性疾病领域。公司依托自主研发的四大技术平台,构建了差异化显著的创新管线,涵盖12款自主研发的ADC候选药物。目前,映恩生物有五项处于临床阶段的资产已获得...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.